Wuhan General Group (China), Inc. (WUHN)
Wuhan General Group (China), Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Cape Town, NV, ZA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $16,545. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -12086.9%. Its beta of -1.21 implies it has historically moved less than the broad market.
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
Wuhan General Group (China), Inc. is most often compared with the following Healthcare names: